Exploration of Asthma & Allergy

Table 1. Demographics and clinical features of EGPA patients.

Items	Sample
Overall, n	33
Age (years), median [IQR]	60.0 [53.0, 66.0]
Sex, n (%)
Male Female	16 (48.5) 17 (51.5)
Weight (kg), median [IQR]	70.5 [59.0, 81.5]
Height (cm), median [IQR]	169.0 [164.0, 178.0]
Smokers, n (%)
Formers Never Current	6 (18.2) 24 (72.7) 3 (9.1)
FEV₁ (%), median [IQR]	74.0 [65.5, 86.0]
BEC (cells/mm³), median [IQR]	1,950.0 [1,390.0, 2,560.0]
C-ANCA, n (%)	3 (9.1)
P-ANCA, n (%)	8 (24.2)
ECP (μg/L), median [IQR]	60.0 [36.0, 109.0]
SE-IgE, n (%)	18 (54.5)
FLCs (mg/L)
Kappa, median [IQR] Lambda, median [IQR] RATIO κ/λ, median [IQR]	21.1 [15.2, 27.4] 15.7 [12.8, 22.3] 1.26 [1.19, 1.44]
SEA, n (%)	33 (100)
CRSwNP, n (%)	29 (87.8)
CRSwNP number of surgery, median [IQR]	1.0 [0.0, 1.0]
Inhalation therapy, n (%)
ICS/LABA ICS/LABA/LAMA High ICS dose Medium ICS dose Low ICS dose	25 (75.8) 8 (24.2) 11 (33.3) 20 (60.6) 2 (6.1)
OCS therapy, n (%)
Prednisone (or equivalent) ≥ 7.5 mg	27 (81.8)
Biologics, n (%)	16 (48.5)
Immunosuppressant, n (%)	9 (27.3)
ACQ-5, median [IQR]	0.5 [0.2, 0.6]
ACT, median [IQR]	18.0 [12.0, 23.0]
SNOT-22, median [IQR]	80.0 [52.5, 80.0]
Peripheric neuropathy, n (%)	20 (60.6)

Return to article view

ACQ-5: 5-item Asthma Control Questionnaire; ACT: Asthma Control Test; BEC: blood eosinophil count; C-ANCA: cytoplasmic antineutrophil cytoplasmic antibody; CRSwNP: chronic rhinosinusitis with nasal polyp; ECP: eosinophilic cationic protein; EGPA: eosinophilic granulomatosis with polyangiitis; FEV₁: forced expiratory volume in 1 second; FLCs: free light chains; ICS: inhaled corticosteroids; IQR: interquartile range; LABA: long-acting beta-agonists; LAMA: long-acting muscarinic antagonists; OCS: oral corticosteroid; P-ANCA: perinuclear antineutrophil cytoplasmic antibody; PR3: proteinase-3; SEA: severe eosinophilic asthma; SE-IgE: specific IgE to staphylococcal enterotoxins; SNOT-22: 22-item Sino-Nasal Outcome Test.

Declarations

Author contributions

CC: Project administration, Conceptualization, Methodology, Investigation, Writing—original draft, Writing—review & editing, Supervision, Validation, Data curation. IB: Project administration, Conceptualization, Methodology, Investigation, Writing—original draft, Writing—review & editing, Supervision, Validation, Data Curation. SC, MR, E De Corso, GBC, PA, AD, EG, BB, VP, and SDG: Writing—review & editing, Supervision. MAZ, DL, CL, LB, GL, FRS, and GC: Data Curation, Writing—review & editing, Supervision. E Di Carluccio, UB, and BN: Data Curation, Formal analysis. AG: Supervision, Visualization. All authors read and approved the submitted version.

Conflicts of interest

Vincenzo Patella, who is the Editorial Board Member and Guest Editor of Exploration of Asthma & Allergy, had no involvement in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.

Ethical approval

The study was approved by the Comitato Etico Territoriale Lazio Area 3 Ethics Committee (ID 6154) and complies with the Declaration of Helsinki.

Consent to participate

Patientsʼ informed consent was obtained for data collection, analysis, and publication.

Consent to publication

Patientsʼ informed consent was obtained for data collection, analysis, and publication.

Availability of data and materials

Data are available upon reasonable request to the corresponding author.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19:378–93. [DOI] [PubMed]

Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022;81:309–14. [DOI] [PubMed]

Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, et al. International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med. 2020;202:1360–72. [DOI] [PubMed]

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021;73:1366–83. [DOI] [PubMed] [PMC]

Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, et al. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus. J Allergy Clin Immunol Pract. 2023;11:3629–37. [DOI] [PubMed]

Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70–88. [DOI] [PubMed] [PMC]

Kallenberg CGM. Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Curr Opin Rheumatol. 2016;28:8–14. [DOI] [PubMed]

Singh T, Bello B, Jeebhay MF. Characterizing Inflammatory Cell Asthma Associated Phenotypes in Dental Health Workers Using Cytokine Profiling. Front Allergy. 2021;2:747591. [DOI] [PubMed] [PMC]

Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673–80. [PubMed]

10.

Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7. [DOI] [PubMed]

11.

Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117:549–56. [DOI] [PubMed]

12.

Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34:447–54. [DOI] [PubMed]

13.

2024 GINA Main Report: Global Strategy for Asthma Management and Prevention [Internet]. Global Initiative for Asthma; c2024 [cited 2026 Feb 15]. Available from: https://ginasthma.org/2024-report/

14.

Rout P, Maher L. Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. [PubMed]

15.

Ledda AG, Costanzo G, Sambugaro G, Caruso C, Bullita M, Martino MLD, et al. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab. Life (Basel). 2023;13:1884. [DOI] [PubMed] [PMC]

16.

Lu P, Lee T, Huang C, Chang P, Chen Y, Fu C. Serum eosinophil cationic protein: a prognostic factor for early postoperative recurrence of nasal polyps. Int Forum Allergy Rhinol. 2021;11:766–72. [DOI] [PubMed]

17.

Didehdar M, Khoshbayan A, Vesal S, Darban-Sarokhalil D, Razavi S, Chegini Z, et al. An overview of possible pathogenesis mechanisms of Alternaria alternata in chronic rhinosinusitis and nasal polyposis. Microb Pathog. 2021;155:104905. [DOI] [PubMed]

18.

Caruso C, Ciasca G, Baglivo I, Santo RD, Gasbarrini A, Firinu D, et al. Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker? Allergy. 2024;79:2414–22. [DOI] [PubMed]

19.

Ueno M, Kobayashi S, Asakawa S, Arai S, Nagura M, Yamazaki O, et al. Emergence of proteinase 3-antineutrophil cytoplasmic antibody-associated glomerulonephritis with mesangial immune deposition during the clinical course of IgG λ monoclonal gammopathy of uncertain significance. CEN Case Rep. 2022;11:463–70. [DOI] [PubMed] [PMC]

20.

Mukherjee M, Nair P. Autoimmune Responses in Severe Asthma. Allergy Asthma Immunol Res. 2018;10:428–47. [DOI] [PubMed] [PMC]

21.

Caminati M, Fassio A, Alberici F, Baldini C, Bello F, Cameli P, et al. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group. Allergy. 2024;79:516–9. [DOI] [PubMed]